Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from AstraZeneca ( (GB:AZN) ).
AstraZeneca PLC has published its Annual Report and Form 20-F Information for 2024, which is available on the company’s website and will soon be accessible via the National Storage Mechanism. The report includes key regulated information such as principal risks, directors’ responsibilities, and related party transactions. The company’s Annual General Meeting is scheduled for April 11, 2025. This announcement highlights AstraZeneca’s commitment to transparency and regulatory compliance, potentially influencing its stakeholders and market positioning.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, UK. It specializes in the discovery, development, and commercialization of prescription medicines within the fields of Oncology, Rare Diseases, and BioPharmaceuticals, which encompass Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca’s innovative medicines are distributed in over 125 countries and are utilized by millions of patients worldwide.
YTD Price Performance: 11.90%
Average Trading Volume: 2,726,647
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: £181.6B
See more insights into AZN stock on TipRanks’ Stock Analysis page.
